Development, Commercialization and Supply Agreement - Additional Information (Detail)	1 Months Ended							3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 31, 2021 USD ($)	Feb. 29, 2020 USD ($)	Jan. 31, 2020 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Mar. 31, 2016 USD ($)	Feb. 28, 2015 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2021 USD ($) Item	Jun. 30, 2020 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2019 USD ($)
License And Collaboration Agreements [Line Items]
Revenue recognized related to upfront and milestone payments										$ 1,225,000	$ 4,382,000
Licenses revenue								$ 154,488,000	$ 135,317,000	296,658,000	290,310,000
Deferred revenue								17,468,000	20,214,000	17,468,000	20,214,000	$ 18,632,000		$ 20,846,000
Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue								153,773,000	133,724,000	$ 295,156,000	285,928,000
Mochida Pharmaceutical Co., Ltd. | In-licenses
License And Collaboration Agreements [Line Items]
Milestones payment	$ 1,000,000.0											1,000,000.0
Mochida Pharmaceutical Co., Ltd. | In-licenses | Research and Development Expense
License And Collaboration Agreements [Line Items]
Upfront payment													$ 2,700,000
Edding | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received							$ 15,000,000.0
Number of indications of the regulatory milestone events relating to the submission and approval | Item										3
Amounts to be received upon achievement of the regulatory milestone events								33,000,000.0		$ 33,000,000.0
Sales-based milestone event payment								120,000,000.0		120,000,000.0
Revenue recognized related to upfront and milestone payments										600,000	1,600,000
Deferred revenue								10,200,000		10,200,000		10,800,000
Edding | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue										6,700,000		6,100,000
Edding | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone								153,000,000.0		153,000,000.0
Amounts to be received upon achievement of the regulatory milestone events								15,000,000.0		15,000,000.0
Sales-based milestone event payment								50,000,000.0		50,000,000.0
Edding | Out-licenses | Minimum
License And Collaboration Agreements [Line Items]
Amounts to be received upon achievement of the regulatory milestone events								2,000,000.0		2,000,000.0
Sales-based milestone event payment								5,000,000.0		5,000,000.0
Edding | Out-licenses | Clinical Trial Application
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received						$ 1,000,000.0
Biologix FZCo | Out-licenses
License And Collaboration Agreements [Line Items]
Revenue recognition period of non-refundable up-front payment						10 years
Biologix FZCo | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue										500,000
HLS | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received					$ 5,000,000.0
Non-refundable milestone payment received		$ 2,500,000	$ 3,800,000	$ 2,500,000	$ 2,500,000
Revenue recognized related to upfront and milestone payments										600,000	2,700,000
Deferred revenue								6,500,000		6,500,000		7,100,000
Non-refundable up-front received period					6 months
Non-refundable milestone payment received					$ 3,800,000
HLS | Out-licenses | Health Canada
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received					2,500,000
HLS | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue										7,200,000		$ 6,600,000
HLS | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue									$ 1,800,000		$ 8,500,000
HLS | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone					$ 50,000,000.0